Abstract
Metastatic colorectal cancer currently, despite the inclusion of modern biological drugs and deepening cooperation with surgeons and interventional radiologists still among disease where most patients can achieve significant prolongation of survival, but not a cure. Median overall survival in published studies varies widely from 23 to 42 months, depending on the size of the cohort, selecting patients according mutation status RAS and BRAF and other factors.
Colorectal cancers involving mutations RAS are associated with aggressive behavior and a shorter overall survival. The median overall survival of patients whose disease had progressed during first line palliative treatment, with studies charting the effectiveness of anti-VEGF and anti-EGFR drugs ranges from 10 to 16 months, median progression-free survival is 5,7-7, 3 months and frequency of objective response rate amounts to 5,4-33%.